Summary
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
Description
THE PHARMACEUTICAL MARKET: UKRAINE - REVIEW
The Ukrainian pharmaceutical market is the poorest in the region in per capita terms, but growth is expected to be strong over the next few years. Whilst Ukraine was hit hard by the economic crisis, the economy is recovering and this will help to boost the performance of the pharmaceutical market. The market is driven by strong import growth; this is expected to remain strong due to a lack of locally manufactured innovative products. The pharmaceutical market could also grow more rapidly if the government manages to implement an effective health insurance system.
In June 2011, the Cabinet of Ministers adopted the state target scientific-technical programme for the development of new technologies to create domestic pharmaceuticals, which is designed to meet the human and veterinary medicinal needs of 2011-2015. State funding will account for almost half of the budget for the programme. A quarter of state funding will be used for the research and development of molecular and cellular technologies for creating biologically active substances. Investment funds will be used primarily to purchase modern equipment for the production of innovative medicinal substances, including immunological agents, vaccines and recombinant proteins.
Ongoing political difficulties and frequent changes in the leadership of the MoH have led to protracted delays in health system reform. The development of health insurance was also hindered by the recent financial crisis, which led to significant devaluation of the currency. The introduction of health insurance has been further impeded by the demographic situation; the ageing population and the impending rise in the death rate would severely reduce the number of potential payers into the insurance system. However, in 2011, Deputy Parliament Speaker, Tetiana Bakhteeva, predicted that the health system will be ready for comprehensive health insurance by 2014.
ENHANCED STRATEGIC INTELLIGENCE
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
The Pharmaceutical Market: Ukraine published by Espicom Business Intelligence in January 31, 2013. This report consists of 100 Pages and the price starts from US $ 1295.
The contents of this page may be different from the latest version. Please contact us for details.
